Document Specialty Meds in the EHR, Even if You're NOT the Prescriber

You'll hear more about specialty meds...Repatha (evolocumab), Harvoni (ledipasvir/sofosbuvir), Gleevec (imatinib), etc.

Specialty meds account for about half of new drugs approved in 2015...and these meds will make up over half of drug spending by 2017.

What makes specialty meds "special"? They're generally high-cost and "high-touch"...such as requiring specific testing before starting the med, a detailed monitoring plan, or unique storage.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote